EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Possibility of PD-1/PD-L1 Inhibitors for the Treatment of Patients with Chronic Hepatitis B Infection

Menghan Su, Ting Ye, Wei Wu, Zheyue Shu, Qi Xia

Digestive Diseases · 2024 · 42 (1) · 53-60

DOI: 10.1159/000534535 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Digestive Diseases, online erschienen am 11.10.2023. Verfasst von Menghan Su und 4 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Inn…. Hauptthemen laut MEDLINE: Hepatitis B, Chronic, Hepatitis B. Die Arbeit wurde bisher 15-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background: Chronic hepatitis B (CHB) infection is still a major global public health problem, with nearly two billion patients. Although current antiviral drugs can inhibit viral replication and reduce hepatitis B virus (HBV) related complications, it is difficult to achieve clinical endpoints due to drug resistance. Summary: Immune checkpoint inhibitors (ICIs) are an important strategy to reverse T-cell exhaustion, and rebuilding an effective functional T-cell response is a promising immunomodulatory approach for CHB patients. However, ICIs may lead to viral reactivation or immune-related adverse effects. There are still many controversies in the application of ICIs in treating patients with CHB. Key Messages: This article reviews the research progress of ICIs in CHB infection and related issues. The goal of this paper was to summarize the possible impact of new therapies for CHB with the aim of reducing potential clinical risks.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatitis B, ChronicHepatitis BHumansImmune Checkpoint InhibitorsProgrammed Cell Death 1 ReceptorHepatitis B virusCD8-Positive T-LymphocytesAntiviral Agents

Stichwörter der Autor:innen

CD8+ T lymphocytesHepatitis B virusImmune checkpoint inhibitorsPD-1/PD-L1 inhibitors

Substanzen

Immune Checkpoint InhibitorsProgrammed Cell Death 1 ReceptorAntiviral Agents

Autor:innen und Institutionen

  • State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The…
  • Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
  • NHC Key Laboratory of Combined Multi-Organ Transplantation, Hangzhou, China.
  • Key Laboratory of the Diagnosis and Treatment of Organ Transplantation, Research Unit of Collaborative Diagnosis and Treatment for Hepatobiliary and Pancreatic Cancer, Chinese Academy of Medical Sciences, Hangzhou, Chin…
  • Key Laboratory for Biomedical Engineering of Ministry of Education, Zhejiang University, Hangzhou, China.

Zitieren

APA

Su, M., Ye, T., Wu, W., Shu, Z., & Xia, Q. (2024). Possibility of PD-1/PD-L1 Inhibitors for the Treatment of Patients with Chronic Hepatitis B Infection. Digestive Diseases, 42(1), 53-60. https://doi.org/10.1159/000534535

Vancouver

Su M, Ye T, Wu W, Shu Z, Xia Q. Possibility of PD-1/PD-L1 Inhibitors for the Treatment of Patients with Chronic Hepatitis B Infection. Digestive Diseases. 2024;42(1):53-60. doi:10.1159/000534535

BibTeX
@article{Su2024,
  author = {Su, Menghan and Ye, Ting and Wu, Wei and Shu, Zheyue and Xia, Qi},
  title = {Possibility of PD-1/PD-L1 Inhibitors for the Treatment of Patients with Chronic Hepatitis B Infection},
  journal = {Digestive Diseases},
  year = {2024},
  volume = {42},
  number = {1},
  pages = {53--60},
  doi = {10.1159/000534535}
}
Kostenlos starten →